FOLFIRI

Results: 24



#Item
11Overall survival in all RAS wild type patients in CALGB/SWOGstudy

Overall survival in all RAS wild type patients in CALGB/SWOGstudy

Add to Reading List

Source URL: www.pbs.gov.au

Language: English - Date: 2015-03-16 01:05:14
12切除不能大腸癌の二次治療例に対するCPT-11+5-FU+l-LV（FOLFIRI）療法と CPT-11+TS-1（IRIS）療法の第２／３相臨床試験（FIRIS）

切除不能大腸癌の二次治療例に対するCPT-11+5-FU+l-LV（FOLFIRI）療法と CPT-11+TS-1（IRIS）療法の第２／３相臨床試験（FIRIS）

Add to Reading List

Source URL: www.taiho.co.jp

Language: Japanese - Date: 2012-01-23 21:10:52
    13Microsoft WordCRC Disease Site Schema

    Microsoft WordCRC Disease Site Schema

    Add to Reading List

    Source URL: www.ucdenver.edu

    Language: English - Date: 2015-04-03 14:22:01
    14IMPORTANT: PLEASE READ tolerate other irinotecan-based chemotherapy. PART III: CONSUMER INFORMATION  In patients who cannot tolerate irinotecan.  In patients who have failed on both irinotecan- and Pr

    IMPORTANT: PLEASE READ tolerate other irinotecan-based chemotherapy. PART III: CONSUMER INFORMATION  In patients who cannot tolerate irinotecan.  In patients who have failed on both irinotecan- and Pr

    Add to Reading List

    Source URL: www.bmscanada.ca

    Language: English - Date: 2014-01-17 12:57:49
    15Effect of Gender on Coagulation Functions: A Study in Metastatic Colorectal Cancer Patients Treated with Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin

    Effect of Gender on Coagulation Functions: A Study in Metastatic Colorectal Cancer Patients Treated with Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin

    Add to Reading List

    Source URL: www.ncbi.nlm.nih.gov

    Language: English
    16Microsoft Word - Erbitux_E_PM_14 Jan 2014_DIST_CLN

    Microsoft Word - Erbitux_E_PM_14 Jan 2014_DIST_CLN

    Add to Reading List

    Source URL: www.bmscanada.ca

    Language: English - Date: 2014-01-17 12:53:56
    17Primary End Points - To assess the efficacy of OCZ103-OS in prolonging overall survival duration in metastatic colorectal cancer patients treated concurrently with mFOLFOX6 or FOLFIRI - To assess the efficacy of OCZ103-O

    Primary End Points - To assess the efficacy of OCZ103-OS in prolonging overall survival duration in metastatic colorectal cancer patients treated concurrently with mFOLFOX6 or FOLFIRI - To assess the efficacy of OCZ103-O

    Add to Reading List

    Source URL: www.colorectal-cancer.ca

    Language: English - Date: 2012-02-14 09:07:12
    18HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZALTRAP safely and effectively. See full prescribing information for ZALTRAP. ZALTRAP® (ziv-aflibercept) Injection

    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZALTRAP safely and effectively. See full prescribing information for ZALTRAP. ZALTRAP® (ziv-aflibercept) Injection

    Add to Reading List

    Source URL: www.accessdata.fda.gov

    Language: English - Date: 2012-08-03 13:42:37
    19HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZALTRAP safely and effectively. See full prescribing information for ZALTRAP. ZALTRAP® (ziv-aflibercept) Injection

    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZALTRAP safely and effectively. See full prescribing information for ZALTRAP. ZALTRAP® (ziv-aflibercept) Injection

    Add to Reading List

    Source URL: www.accessdata.fda.gov

    Language: English - Date: 2013-10-31 17:25:23
    20CLINICAL PRACTICE GUIDELINE GI-003 version 7 METASTATIC COLORECTAL CANCER Effective Date: March, 2014

    CLINICAL PRACTICE GUIDELINE GI-003 version 7 METASTATIC COLORECTAL CANCER Effective Date: March, 2014

    Add to Reading List

    Source URL: www.albertahealthservices.ca

    Language: English - Date: 2014-03-28 17:58:19